Long Term Follow-up Observational Study After Clinical Trials of AMG531

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03025698` - A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia	Phase 2
Completed	`NCT00987480` - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Phase 2
Completed	`NCT00767650` - Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia	N/A
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Not yet recruiting	`NCT02833493` - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload	N/A
Recruiting	`NCT02028416` - Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia	N/A
Completed	`NCT00004474` - Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia	Phase 3
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Completed	`NCT04439006` - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	Phase 1
Not yet recruiting	`NCT05996393` - CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly	Phase 4
Completed	`NCT02462252` - Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	Phase 2
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A
Completed	`NCT00513175` - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia	N/A
Completed	`NCT00001398` - Stem Cell Factor Medication for Aplastic Anemia	Phase 1
Recruiting	`NCT01861093` - Safety Study of Cord Blood Units for Stem Cell Transplants	Phase 2
Not yet recruiting	`NCT05018936` - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia	Phase 2/Phase 3
Completed	`NCT00065260` - Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia	Phase 2
Recruiting	`NCT02007811` - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination	Phase 1/Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Terminated	`NCT01500161` - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match	Phase 2

NCT number	NCT04870346
Study type	Observational
Source	Kyowa Kirin Co., Ltd.
Contact
Status	Enrolling by invitation
Phase
Start date	May 10, 2021
Completion date	June 30, 2024

Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms